Key Points
- Hims & Hers Health CFO Oluyemi Okupe sold 7,950 shares on May 18 at an average price of $23.64, totaling about $187,938. The trade was made under a pre-arranged Rule 10b5-1 plan, and his ownership fell by 2.93%.
- The company recently missed earnings expectations, reporting a Q1 loss of $0.40 per share versus the expected $0.04 loss and revenue of $608.1 million versus $616.84 million estimated. Revenue still grew 3.8% year over year, but sentiment remains pressured after the miss.
- Analysts are cautious on HIMS, with several firms cutting price targets and the stock carrying an average “Hold” rating and a consensus target of $29.37. Investors are also watching the company’s upsized $350 million convertible notes offering, which may support expansion but raises dilution concerns.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 7,950 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. This trade represents a 2.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20.
- On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80.
- On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.
- On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total transaction of $79,420.50.
- On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09.
Hims & Hers Health Stock Up 0.8%
Shares of NYSE:HIMS opened at $22.47 on Wednesday. The stock has a market capitalization of $5.12 billion, a price-to-earnings ratio of -249.61, a price-to-earnings-growth ratio of 39.32 and a beta of 2.43. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The company's fifty day moving average is $24.05 and its two-hundred day moving average is $28.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the company posted $0.20 earnings per share. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.
Key Headlines Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
Analysts Set New Price Targets
A number of research firms recently weighed in on HIMS. JPMorgan Chase & Co. dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, May 12th. TD Cowen dropped their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating on the stock in a report on Friday, March 27th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. BTIG Research reaffirmed a "neutral" rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group set a $32.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and an average target price of $29.37.
Check Out Our Latest Report on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
Several large investors have recently bought and sold shares of the stock. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Silicon Valley Capital Partners bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $48,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Finally, Bogart Wealth LLC boosted its holdings in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
